Companies › Affini-T Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AFNT-211 Engineered TCR T-cell recognizing KRAS G12V | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06105021 | AFNT-211 | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.